Human cytomegalovirus (HCMV) is a β-herpesvirus with the largest genome of any known human pathogen. Its sophisticated immune evasion — including cell-to-cell spread and glycoprotein-mediated immune shielding — makes antibody design uniquely demanding. MAbSilico engineers next-generation anti-HCMV antibodies targeting gB and the pentameric complex, with IgG1-based Fc engineering for ADCC/ADCP and YTE half-life extension, from a curated database of 380+ annotated antibody sequences.
HCMV employs a multi-stage entry process governed by four distinct glycoprotein complexes. Effective antibody design requires understanding which complexes mediate entry into which cell types — the source of HCMV's unique tropism.
HCMV's entry mechanism varies by cell type. The Pentameric Complex (PC = gH/gL/UL128/UL130/UL131A) is required for entry into epithelial, endothelial and myeloid cells via a low-pH endocytic pathway. The Trimer complex (gH/gL/gO) mediates fibroblast infection. Glycoprotein B (gB) is the essential Class III fusogen across all susceptible cell types.
Neutralizing antibodies against the PC — such as LJP539 and MCMV3068A — exhibit potencies three to four orders of magnitude greater than anti-gB antibodies in epithelial cell lines. This makes the PC the primary high-value engineering target for broad non-fibroblast protection.
HCMV can disseminate directly between adjacent cells in a "cloaked" manner that avoids circulating antibodies. It can also incorporate neutralizing antibodies into newly forming virions — using the Fc domain to facilitate entry via Fc-receptor pathways (antibody-dependent enhancement). This makes Fc-mediated effector functions (ADCC, ADCP) critical for clearing infected cells beyond free virion neutralization.
| Glycoprotein Complex | Components | Target Cell Types |
|---|---|---|
| Glycoprotein B (gB) | gB Homotrimer | All susceptible cells — Class III fusogen for membrane fusion |
| Trimer Complex | gH / gL / gO | Fibroblasts — receptor-mediated fusion |
| Pentameric Complex (PC) | gH/gL/UL128/UL130/UL131A | Epithelial · Endothelial · Myeloid — endocytosis pathway |
| gM/gN Complex | gM/gN Heterodimer | Broadly relevant — attachment and maturation |
Effective anti-HCMV antibodies combine direct viral neutralization with immune effector recruitment — a dual requirement that drives both IgG subclass choice and Fc engineering strategy.
IgG1 subclass is the primary choice for HCMV antibodies because it delivers superior ADCC and ADCP through high-affinity binding to FcγRI, FcγRIIa and FcγRIIIa receptors. In the Roche RG7667 cocktail, both MCMV5322A (anti-gB) and MCMV3068A (anti-PC) were engineered as IgG1 to ensure dual neutralization and effective clearance of infected cells. CSJ148 (Novartis) similarly utilized human IgG1 to maximize immune-mediated viral clearance in HSCT patients.
YTE mutation (M252Y/S254T/T256E) is the established technique for half-life extension in prophylactic HCMV antibodies. By increasing FcRn affinity at endosomal pH, the antibody is recycled into circulation rather than degraded — extending serum half-life from ~21 to 60+ days, enabling less frequent dosing in immunosuppressed transplant patients.
| IgG Subclass | Serum t½ | FcγR Affinity | Use in HCMV |
|---|---|---|---|
| IgG1 | ~21 days | High (multiple FcγR) | Primary choice — neutralization + ADCC/ADCP |
| IgG2 | ~21 days | Low (FcγRIIa only) | Rare — when effector function is undesirable |
| IgG4 | ~21 days | Moderate (FcγRI only) | Blocking without immune activation |
MAbSilico advantage: Our platform screens the complete HCMV antibody database to identify optimal gB + PC pairing combinations, then applies multiparametric optimization for affinity, ADCC potency, YTE compatibility and developability — simultaneously.
The clinical field has shifted from polyclonal hyperimmune immunoglobulin toward highly engineered monoclonal antibodies and cocktails, driven by the precision requirements of gB and PC targeting.
Anti-HCMV antibody programs target three distinct clinical settings: solid organ transplant (SOT) recipients at risk of HCMV reactivation, hematopoietic stem cell transplant (HSCT) patients where HCMV causes life-threatening pneumonia and retinitis, and prevention of congenital CMV (cCMV) — the leading cause of non-genetic sensorineural hearing loss and neurodevelopmental disability. Each setting has distinct requirements for dosing schedule, Fc engineering, and target glycoprotein prioritization.
Our 6-step workflow applies to every HCMV glycoprotein target — from structural analysis of gB and the pentameric complex to ready-to-clone sequences with Fc-engineering built in.
Whether you need a gB blocker, a PC-targeting cocktail, or a YTE-extended prophylactic — MAbSilico's platform designs Phase-I-ready anti-HCMV candidates from the world's most curated HCMV antibody dataset.